Inozyme Pharma, Inc. (INZY)
Jul 1, 2025 - INZY was delisted (reason: acquired by BMRN)
4.000
0.00 (0.00%)
Inactive · Last trade price
on Jun 30, 2025
Inozyme Pharma Employees
Inozyme Pharma had 67 employees as of December 31, 2024. The number of employees increased by 8 or 13.56% compared to the previous year.
Employees
67
Change (1Y)
8
Growth (1Y)
13.56%
Revenue / Employee
n/a
Profits / Employee
-$1,592,776
Market Cap
259.66M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 67 | 8 | 13.56% |
Dec 31, 2023 | 59 | 3 | 5.36% |
Dec 31, 2022 | 56 | 6 | 12.00% |
Dec 31, 2021 | 50 | 12 | 31.58% |
Dec 31, 2020 | 38 | - | - |
INZY News
- 9 days ago - BioMarin Announces Completion of Acquisition of Inozyme - PRNewsWire
- 20 days ago - Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders - GlobeNewsWire
- 7 weeks ago - INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY - Business Wire
- 7 weeks ago - BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma - PRNewsWire
- 2 months ago - Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights - GlobeNewsWire
- 3 months ago - Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency - GlobeNewsWire
- 3 months ago - Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 4 months ago - Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights - GlobeNewsWire